ArticleBMC medical genetics2013
Detailed investigations of proximal tubular function in Imerslund-Gräsbeck syndrome.
Article in BMC medical genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Nonprogressive Nephrotic Range Proteinuria Because of Indirect Cubilin Dysfunction.Kidney international reports · 2026Article
- ProteinMolecules (Basel, Switzerland) · 2025Review
- Vitamin B12 deficiency in a young male with Imerslund-Gräsbeck syndrome: case report.Frontiers in pediatrics · 2025Article
- To treat or not to treat: CUBN-associated persistent proteinuria.Kidney research and clinical practice · 2024Article
- Vitamin BInternational journal of molecular sciences · 2024Review
- Controversy between biopsy and risk in children with proteinuria: is there a paradigm war?BMC nephrology · 2024Article
- A child with megaloblastic anemia and proteinuria: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- Renal Handling of Albumin-From Early Findings to Current Concepts.International journal of molecular sciences · 2021Review
- Protective Role of Vitamin D in Renal Tubulopathies.Metabolites · 2020Review
- Vitamin D Therapy and the Era of Precision Medicine.The Journal of clinical endocrinology and metabolism · 2020Article
- Not all proteinuria is created equal.The Journal of clinical investigation · 2020Article
- Profound vitamin D deficiency in four siblings with Imerslund-Grasbeck syndrome with homozygous CUBN mutation.JIMD reports · 2019Article
- The Spectrum of Kidney Diseases in Children Associated with Low Molecular Weight Proteinuria.Open access Macedonian journal of medical sciences · 2018Article
- ORAI channels are critical for receptor-mediated endocytosis of albumin.Nature communications · 2017Article
- Endocytic receptor LRP2/megalin-of holoprosencephaly and renal Fanconi syndrome.Pflugers Archiv : European journal of physiology · 2017Review
- Proximal Tubular Expression Patterns of Megalin and Cubilin in Proteinuric Nephropathies.Kidney international reports · 2017Article
- Interactions of vitamin D and the proximal tubule.Pediatric nephrology (Berlin, Germany) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImerslund-Gräsbeck Syndrome (IGS) is a rare genetic disorder characterised by juvenile megaloblastic anaemia. IGS is caused by mutations in either of the genes encoding the intestinal intrinsic factor-vitamin B12 receptor complex, cubam. The cubam receptor proteins cubilin and amnionless are both expressed in the small intestine as well as the proximal tubules of the kidney and exhibit an interdependent relationship for post-translational processing and trafficking. In the proximal tubules cubilin is involved in the reabsorption of several filtered plasma proteins including vitamin carriers and lipoproteins. Consistent with this, low-molecular-weight proteinuria has been observed in most patients with IGS. The aim of this study was to characterise novel disease-causing mutations and correlate novel and previously reported mutations with the presence of low-molecular-weight proteinuria.
methodsGenetic screening was performed by direct sequencing of the CUBN and AMN genes and novel identified mutations were characterised by in silico and/or in vitro investigations. Urinary protein excretion was analysed by immunoblotting and high-resolution gel electrophoresis of collected urines from patients and healthy controls to determine renal phenotype.
resultsGenetic characterisation of nine IGS patients identified two novel AMN frameshift mutations alongside a frequently reported AMN splice site mutation and two CUBN missense mutations; one novel and one previously reported in Finnish patients. The novel AMN mutations were predicted to result in functionally null AMN alleles with no cell-surface expression of cubilin. Also, the novel CUBN missense mutation was predicted to affect structural integrity of the IF-B12 binding site of cubilin and hereby most likely cubilin cell-surface expression. Analysis of urinary protein excretion in the patients and 20 healthy controls revealed increased urinary excretion of cubilin ligands including apolipoprotein A-I, transferrin, vitamin D-binding protein, and albumin. This was, however, only observed in patients where plasma membrane expression of cubilin was predicted to be perturbed.
conclusionsIn the present study, mutational characterisation of nine IGS patients coupled with analyses of urinary protein excretion provide additional evidence for a correlation between mutation type and presence of the characteristic low-molecular-weight proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.